Ladenburg raised the firm’s price target on Kiora Pharmaceuticals to $54 from $6 and keeps a Buy rating on the shares to account for the 1-for-9 reverse split.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KPRX: